University of Michigan Commercialization Agreements Nov 2025
UM Licenses Drug Discovery IP to Enexa Bio Inc
Trusted by teams at
Description
The Regents approved a technology license agreement with Enexa Bio Inc for autoimmune, metabolic, and neurodegenerative disease treatments. The contract includes upfront fees, royalty payments, patent reimbursements, and university equity.
Contract Details
Contract Amount
Equity in Enexa Bio Inc; Upfront fee; Royalties on sales; Patent cost reimbursement
Vendor
ENEXA BIO INC
Agency
University of Michigan Board of Regents, MI
Contract Type
LICENSE
Document Date
November 20, 2025
Renewal Info
May be amended to add related technologies by consent. Equity terms include possible additional equity purchases by university.
More from ENEXA BIO INC
Related Contracts
More from University of Michigan Board of Regents
University of Michigan Regents Communication Report March 2026
University of Michigan Regents Communication Report March 2026
University of Michigan Regents Communication Action Request March 2026
University of Michigan Regents Communication Report March 2026
University of Michigan Regents Communication Action Request March 2026
Want to learn more?
Get alerts on contract renewals, new awards, and vendor activity.
Bring us your territory.
We'll show you what is forming.
See live SLED buying signals, source docs, decision-makers, contract context, and the next step into your CRM or pipeline.